Danicamtiv vs Omecamtiv mecarbil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Cardiac myosin (activator) · full Heart Failure pipeline
Danicamtiv
Developed by Kardigan under a licence from Bristol-Myers Squibb
NCT03447990 · Phase 1/2 · completed
This study was a randomized, quadruple-blind, placebo-controlled phase 1/2 dose-escalation trial in 52 patients, but it was designed to assess safety, tolerability, PK, and pharmacodynamic signals rather than to test a clinical efficacy hypothesis. The primary outcome measures are descriptive safety endpoints with no reported statistical comparisons, and the sample size is small, so despite the sound blinding and control the evidence for danicamtiv is limited. Secondary echocardiographic findings were analyzed by plasma-concentration ranges and are exploratory rather than confirmatory. Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (From first dose to 30 days post last dose (Up to 2 months)); Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts (Baseline, day 1-16, 2 hours pre-dose and at 3-, 5-, 9-, 12-, 24-, and 36-hours post-dose); Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - MAD Cohorts (Baseline, Day 1-16, 2 hours pre-dose and at 7-, 24-, and 48-hours post final dose); Mean Change From Baseline in Vital Signs Part 1 - SAD Cohorts (Baseline and at 6-hours post-dose); Mean Change From Baseline in Vital Signs Part 1 - MAD Cohorts (Baseline and at 6-hours post-dose); Mean Change From Baseline in Vital Signs Part 2 - SAD Cohorts (Baseline and at 6-hours post-dose); Mean Change From Baseline in Vital Signs Part 2 - MAD Cohorts (Baseline and at 6-hours post-dose); Number of Participants With a Troponin I Increase - SAD Cohorts (Baseline, day 1-3, 2 hours pre-dose and at 3-, 5-, 9-, 12-, 24-, and 36-hours post-dose); Number of Participants With a Troponin I Increase - MAD Cohorts (Baseline, pre-dose and 7hr post dose on treatment day 1, day 2, day 5 and pre-dose and at 7-, 24-, and 48-hours post final dose); Number of Participants With Clinically Significant Laboratory Abnormalities (From first dose to 30 days post last dose (Up to 2 months)); Number of Participants With Clinically Significant Physical Examinations Abnormalities (From first dose to 30 days post last dose (Up to 2 months)): Troponin I increase: 3/12 danicamtiv vs 0/12 placebo in SAD cohorts; 7/30 danicamtiv vs 0/10 placebo in MAD cohorts. (not_applicable)
Result source: NCT03447990
Omecamtiv mecarbil
Developed by Cytokinetics and partners
NCT02929329 · Phase 3 · completed
This was a large, randomized, triple-blind, placebo-controlled trial involving 8,256 participants. Its hard clinical primary endpoint—time to cardiovascular death or first heart-failure event—was met, favoring omecamtiv mecarbil (hazard ratio 0.92, p=0.0252).
Next expected readout: September 2027 · NCT06736574 (registry estimate)
Reported efficacy
Time to Cardiovascular Death or First Heart Failure Event (From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.): Time to Cardiovascular Death or First Heart Failure Event (From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.): Omecamtiv Mecarbil 37% vs Placebo 39.1% (met)
Result source: NCT02929329
Results for Heart Failure
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Danicamtiv | Omecamtiv mecarbil |
|---|---|---|
| CV death or HF hospitalisation | —Not reported | 37% vs 39.1%−2.1 vs placeboNCT02929329 |
| HF hospitalisation | —Not reported | 27.7% vs 28.7%−1 vs placeboNCT02929329 |
| CV death | —Not reported | 19.6% vs 19.4%+0.2 vs placeboNCT02929329 |
| KCCQ clinical summary, change | —Not reported | —Trial running · NCT06736574 |
CV death or HF hospitalisation
- Danicamtiv
- —Not reported
- Omecamtiv mecarbil
- 37% vs 39.1%−2.1 vs placeboNCT02929329
HF hospitalisation
- Danicamtiv
- —Not reported
- Omecamtiv mecarbil
- 27.7% vs 28.7%−1 vs placeboNCT02929329
CV death
- Danicamtiv
- —Not reported
- Omecamtiv mecarbil
- 19.6% vs 19.4%+0.2 vs placeboNCT02929329
KCCQ clinical summary, change
- Danicamtiv
- —Not reported
- Omecamtiv mecarbil
- —Trial running · NCT06736574
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Danicamtiv: 2 of 4 rows · Omecamtiv mecarbil: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Danicamtiv | Omecamtiv mecarbil |
|---|---|---|
| Dropout rate | —500 mga NCT03447990 · Phase 1/2 show 8 more results—400 mg NCT03447990 · Phase 1/2 —350 mg NCT03447990 · Phase 1/2 —175 mg NCT03447990 · Phase 1/2 —100 mg NCT03447990 · Phase 1/2 —75 mg NCT03447990 · Phase 1/2 —75 mg NCT03447990 · Phase 1/2 —50 mg NCT03447990 · Phase 1/2 —SAD Cohort 1 Danicamtiv Optional P NCT03447990 · Phase 1/2 | 26.5%b NCT02929329 · Phase 3 · combination · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3 show 28 more results11.4% NCT03759392 · Phase 3 · monotherapy · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3 4.8%25 mg BID NCT02695420 · Phase 2 · registry result, not featured evidence 0%25 mg to 37.5 mg BID Target Dose NCT02695420 · Phase 2 · registry result, not featured evidence 0%25 mg to 50 mg BID Target Dose NCT02695420 · Phase 2 · registry result, not featured evidence 0%50 mg M-F1 NCT01786512 · Phase 2 · registry result, not featured evidence 8.3%50 mg M-F2 NCT01786512 · Phase 2 · registry result, not featured evidence 0%50 mg SCT-F2 NCT01786512 · Phase 2 · registry result, not featured evidence 9.1%25 mg M-F1 NCT01786512 · Phase 2 · registry result, not featured evidence 0%25 mg M-F2 NCT01786512 · Phase 2 · registry result, not featured evidence 0%25 mg SCT-F2 NCT01786512 · Phase 2 · registry result, not featured evidence 3.3%25 mg NCT01786512 · Phase 2 · registry result, not featured evidence 8.1%PK-based titration NCT01786512 · Phase 2 · registry result, not featured evidence 0%MR 100 mg BID NCT00941681 · Phase 2 · registry result, not featured evidence 0%MR 50 mg BID NCT00941681 · Phase 2 · registry result, not featured evidence 9.1%IR 37.5 mg TID NCT00941681 · Phase 2 · registry result, not featured evidence —Cohort 1 Active Drug NCT00682565 · Phase 2 · registry result, not featured evidence —Cohort 2 Active Drug NCT00682565 · Phase 2 · registry result, not featured evidence —2.2 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —1.0 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —1.0 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —1.0 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —0.75 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —0.75 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —0.5 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —0.5 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —0.25 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —0.25 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —0.125 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —500 mga NCT03447990 · Phase 1/2 show 8 more results—400 mg NCT03447990 · Phase 1/2 —350 mg NCT03447990 · Phase 1/2 —175 mg NCT03447990 · Phase 1/2 —100 mg NCT03447990 · Phase 1/2 —75 mg NCT03447990 · Phase 1/2 —75 mg NCT03447990 · Phase 1/2 —50 mg NCT03447990 · Phase 1/2 —SAD Cohort 1 Danicamtiv Optional P NCT03447990 · Phase 1/2 | —b NCT02929329 · Phase 3 · combination · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3 show 28 more results6.5% NCT03759392 · Phase 3 · monotherapy · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3 —25 mg BID NCT02695420 · Phase 2 · registry result, not featured evidence —25 mg to 37.5 mg BID Target Dose NCT02695420 · Phase 2 · registry result, not featured evidence —25 mg to 50 mg BID Target Dose NCT02695420 · Phase 2 · registry result, not featured evidence —50 mg M-F1 NCT01786512 · Phase 2 · registry result, not featured evidence —50 mg M-F2 NCT01786512 · Phase 2 · registry result, not featured evidence —50 mg SCT-F2 NCT01786512 · Phase 2 · registry result, not featured evidence —25 mg M-F1 NCT01786512 · Phase 2 · registry result, not featured evidence —25 mg M-F2 NCT01786512 · Phase 2 · registry result, not featured evidence —25 mg SCT-F2 NCT01786512 · Phase 2 · registry result, not featured evidence —25 mg NCT01786512 · Phase 2 · registry result, not featured evidence —PK-based titration NCT01786512 · Phase 2 · registry result, not featured evidence —MR 100 mg BID NCT00941681 · Phase 2 · registry result, not featured evidence —MR 50 mg BID NCT00941681 · Phase 2 · registry result, not featured evidence —IR 37.5 mg TID NCT00941681 · Phase 2 · registry result, not featured evidence —Cohort 1 Active Drug NCT00682565 · Phase 2 · registry result, not featured evidence —Cohort 2 Active Drug NCT00682565 · Phase 2 · registry result, not featured evidence —2.2 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —1.0 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —1.0 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —1.0 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —0.75 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —0.75 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —0.5 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —0.5 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —0.25 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —0.25 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence —0.125 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%500 mga NCT03447990 · Phase 1/2 show 8 more results0%400 mg NCT03447990 · Phase 1/2 0%350 mg NCT03447990 · Phase 1/2 0%175 mg NCT03447990 · Phase 1/2 0%100 mg NCT03447990 · Phase 1/2 16.7%75 mg NCT03447990 · Phase 1/2 0%75 mg NCT03447990 · Phase 1/2 0%50 mg NCT03447990 · Phase 1/2 0%SAD Cohort 1 Danicamtiv Optional P NCT03447990 · Phase 1/2 | 57.7%b NCT02929329 · Phase 3 · combination · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3 show 28 more results16.2% NCT03759392 · Phase 3 · monotherapy · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3 19%25 mg BID NCT02695420 · Phase 2 · registry result, not featured evidence 5.3%25 mg to 37.5 mg BID Target Dose NCT02695420 · Phase 2 · registry result, not featured evidence 15%25 mg to 50 mg BID Target Dose NCT02695420 · Phase 2 · registry result, not featured evidence 18.2%50 mg M-F1 NCT01786512 · Phase 2 · registry result, not featured evidence 0%50 mg M-F2 NCT01786512 · Phase 2 · registry result, not featured evidence 7.1%50 mg SCT-F2 NCT01786512 · Phase 2 · registry result, not featured evidence 0%25 mg M-F1 NCT01786512 · Phase 2 · registry result, not featured evidence 7.1%25 mg M-F2 NCT01786512 · Phase 2 · registry result, not featured evidence 0%25 mg SCT-F2 NCT01786512 · Phase 2 · registry result, not featured evidence 24%25 mg NCT01786512 · Phase 2 · registry result, not featured evidence 21.9%PK-based titration NCT01786512 · Phase 2 · registry result, not featured evidence 0%MR 100 mg BID NCT00941681 · Phase 2 · registry result, not featured evidence 0%MR 50 mg BID NCT00941681 · Phase 2 · registry result, not featured evidence 9.1%IR 37.5 mg TID NCT00941681 · Phase 2 · registry result, not featured evidence 0%Cohort 1 Active Drug NCT00682565 · Phase 2 · registry result, not featured evidence 2.9%Cohort 2 Active Drug NCT00682565 · Phase 2 · registry result, not featured evidence 100%2.2 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence 0%1.0 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence 0%1.0 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence 0%1.0 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence 0%0.75 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence 0%0.75 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence 0%0.5 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence 5.6%0.5 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence 0%0.25 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence 5.6%0.25 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence 0%0.125 mg/kg/hr NCT00624442 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 500 mga abdominal discomfort 0% (placebo 0%) acute kidney injury 0% (placebo 0%) alanine aminotransferase increased 0% (placebo 0%) NCT03447990 · Phase 1/2 show 8 more results400 mg anaemia 25% (placebo 0%) neck pain 25% (placebo 0%) orthostatic hypotension 25% (placebo 0%) NCT03447990 · Phase 1/2 350 mg bursitis 12.5% (placebo 0%) diarrhoea 12.5% (placebo 0%) hypomagnesaemia 12.5% (placebo 0%) NCT03447990 · Phase 1/2 175 mg blood creatinine increased 12.5% (placebo 0%) dyspnoea 12.5% (placebo 0%) fatigue 12.5% (placebo 0%) NCT03447990 · Phase 1/2 100 mg ventricular tachycardia 33.3% (placebo 0%) arthropod bite 16.7% (placebo 0%) blood creatinine increased 16.7% (placebo 0%) NCT03447990 · Phase 1/2 75 mg vessel puncture site haemorrhage 33.3% (placebo 0%) acute kidney injury 16.7% (placebo 0%) alanine aminotransferase increased 16.7% (placebo 0%) NCT03447990 · Phase 1/2 75 mg fatigue 22.2% (placebo 0%) anaemia 11.1% (placebo 0%) application site rash 11.1% (placebo 0%) NCT03447990 · Phase 1/2 50 mg dermatitis contact 22.2% (placebo 0%) ventricular tachycardia 22.2% (placebo 0%) abdominal discomfort 11.1% (placebo 0%) NCT03447990 · Phase 1/2 cardiac discomfort 16.7% (placebo 0%) dyspnoea 16.7% (placebo 0%) troponin increased 16.7% (placebo 0%) NCT03447990 · Phase 1/2 | b hypotension 6.7% (placebo 5.9%) cardiac failure 6.5% (placebo 7.1%) dyspnoea 6.1% (placebo 6.3%) NCT02929329 · Phase 3 · combination · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3 show 28 more resultsdizziness 4.9% (placebo 5.5%) fatigue 4.9% (placebo 4.4%) diarrhoea 3.8% (placebo 4.4%) NCT03759392 · Phase 3 · monotherapy · Heart Failure, Heart Failure with Reduced Ejection Fraction · phase 3 25 mg BID dehydration 9.5% (placebo 0%) dermatitis 9.5% (placebo 0%) influenza 9.5% (placebo 4.8%) NCT02695420 · Phase 2 · registry result, not featured evidence 25 mg to 37.5 mg BID Target Dose viral upper respiratory tract infection 21.1% (placebo 19%) hypotension 10.5% (placebo 0%) periodontitis 10.5% (placebo 0%) NCT02695420 · Phase 2 · registry result, not featured evidence 25 mg to 50 mg BID Target Dose viral upper respiratory tract infection 20% (placebo 19%) arthralgia 10% (placebo 0%) dizziness 10% (placebo 4.8%) NCT02695420 · Phase 2 · registry result, not featured evidence 50 mg M-F1 headache 18.2% (placebo 0%) muscle spasms 18.2% (placebo 0%) abdominal pain 9.1% (placebo 0%) NCT01786512 · Phase 2 · registry result, not featured evidence 50 mg M-F2 asthenia 9.1% (placebo 0%) nasal congestion 9.1% (placebo 9.1%) pain in extremity 9.1% (placebo 0%) NCT01786512 · Phase 2 · registry result, not featured evidence 50 mg SCT-F2 abnormal faeces 7.1% (placebo 0%) blood alkaline phosphatase increased 7.1% (placebo 0%) flatulence 7.1% (placebo 0%) NCT01786512 · Phase 2 · registry result, not featured evidence 25 mg M-F1 asthenia 10% (placebo 0%) asthma 10% (placebo 0%) bundle branch block left 10% (placebo 0%) NCT01786512 · Phase 2 · registry result, not featured evidence 25 mg M-F2 asthenia 21.4% (placebo 0%) carotid bruit 7.1% (placebo 0%) headache 7.1% (placebo 0%) NCT01786512 · Phase 2 · registry result, not featured evidence 25 mg SCT-F2 headache 38.5% (placebo 0%) dry mouth 7.7% (placebo 0%) insomnia 7.7% (placebo 9.1%) NCT01786512 · Phase 2 · registry result, not featured evidence 25 mg fatigue 9.3% (placebo 0%) dyspnoea 6% (placebo 0%) dizziness 5.3% (placebo 0%) NCT01786512 · Phase 2 · registry result, not featured evidence PK-based titration dyspnoea 8.9% (placebo 0%) dizziness 6.2% (placebo 0%) fatigue 6.2% (placebo 0%) NCT01786512 · Phase 2 · registry result, not featured evidence MR 100 mg BID influenza like illness 8.3% ventricular extrasystoles 8.3% NCT00941681 · Phase 2 · registry result, not featured evidence MR 50 mg BID influenza like illness 0% ventricular extrasystoles 0% NCT00941681 · Phase 2 · registry result, not featured evidence IR 37.5 mg TID influenza like illness 0% ventricular extrasystoles 0% NCT00941681 · Phase 2 · registry result, not featured evidence hypotension 3.2% (placebo 0%) infusion site pain 3.2% (placebo 3.4%) dyspnea 0% (placebo 3.4%) NCT00682565 · Phase 2 · registry result, not featured evidence dyspnea 8.8% (placebo 3.4%) ventricular extrasystoles 5.9% (placebo 0%) hypotension 2.9% (placebo 0%) NCT00682565 · Phase 2 · registry result, not featured evidence 2.2 mg/kg/hr troponin increased 100% (placebo 0%) constipation 0% (placebo 4.9%) dizziness postural 0% (placebo 0%) NCT00624442 · Phase 2 · registry result, not featured evidence 1.0 mg/kg/hr troponin increased 25% (placebo 0%) sinus bradycardia 12.5% (placebo 0%) constipation 0% (placebo 4.9%) NCT00624442 · Phase 2 · registry result, not featured evidence 1.0 mg/kg/hr dizziness postural 16.7% (placebo 0%) hypotension 16.7% (placebo 0%) orthostatic hypotension 16.7% (placebo 4.9%) NCT00624442 · Phase 2 · registry result, not featured evidence 1.0 mg/kg/hr somnolence 6.3% (placebo 2.4%) constipation 0% (placebo 4.9%) dizziness postural 0% (placebo 0%) NCT00624442 · Phase 2 · registry result, not featured evidence 0.75 mg/kg/hr orthostatic hypotension 50% (placebo 4.9%) constipation 0% (placebo 4.9%) dizziness postural 0% (placebo 0%) NCT00624442 · Phase 2 · registry result, not featured evidence 0.75 mg/kg/hr constipation 0% (placebo 4.9%) dizziness postural 0% (placebo 0%) dyspnea 0% (placebo 2.4%) NCT00624442 · Phase 2 · registry result, not featured evidence 0.5 mg/kg/hr urinary tract infection 6.3% (placebo 2.4%) constipation 0% (placebo 4.9%) dizziness postural 0% (placebo 0%) NCT00624442 · Phase 2 · registry result, not featured evidence 0.5 mg/kg/hr dizziness postural 5.6% (placebo 0%) infusion site pain 5.6% (placebo 2.4%) orthostatic hypotension 5.6% (placebo 4.9%) NCT00624442 · Phase 2 · registry result, not featured evidence 0.25 mg/kg/hr constipation 0% (placebo 4.9%) dizziness postural 0% (placebo 0%) dyspnea 0% (placebo 2.4%) NCT00624442 · Phase 2 · registry result, not featured evidence 0.25 mg/kg/hr constipation 5.6% (placebo 4.9%) dizziness postural 5.6% (placebo 0%) dyspnea 5.6% (placebo 2.4%) NCT00624442 · Phase 2 · registry result, not featured evidence 0.125 mg/kg/hr musculoskeletal pain 12.5% (placebo 2.4%) constipation 0% (placebo 4.9%) dizziness postural 0% (placebo 0%) NCT00624442 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 27 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Omecamtiv mecarbil
show 1 more result
show 2 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Danicamtiv's landscape · Omecamtiv mecarbil's landscape